Endometrial cancer Endometrial cancer
Conditions
Interventions
Indocyanine g reen 25mg for injection is dissolved in 5ml of water for injection, and usually 5ml or less is divided into cervical local injections as appropriate. During treatment, indocyanine g ree
Sponsors
Nakamura Keiichiro
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Patients who can obtain written consent from their own involuntary research participation 2. Patients with histolog ically confirmed endometrial cancer. 3. Patients who have been confirmed by pelvic MRI examination and/or abdominal /pelvic CT examination as preoperative examination and no patholog ical enlarg ement of lymph nodes 4. Patients scheduled for robot-assisted surg ery for endometrial cancer malig nant tumor 5. Patients ag e 20 to 70 years at the time of reg istration 6. Patients whose g eneral status is 0 or 1 7. Patients with no previous history of radiation therapy, chemotherapy, or surg ery 8.Patients with major org an functions Neutrophil count 2000 / mm3 or more , Hemog lobin 10g / dl or more (correction by blood transfusion is permitted) , Platelet count 100,000 / mm 3 or more , Total bilirubin 1.5mg / dl AST (GOT) and ALT (GPT) 100 IU / l or lessSerum creatinine 1.2mg / dl or less 9. The following tests must be performed within 28 days prior to the operation,The ECG test should not show normal, and abnormal finding s requiring treatment.
Exclusion criteria
Exclusion criteria: 1.Patients with active double cancer (simultaneous double cancer and metachronous double cancer with a disease-free period of 5 years or less). However, lesions equivalent to intraepithelial cancer or intramucosal cancer that are judg ed to be cured by local treatment are not included in active double cancer. 2. Patients with a history of indocyanine g reen sensitivity or iodine sensitivity 3. Patients with severe obesity 4.Patients who are considered difficult to participate in the study due to complications of heart disease and g laucoma 5. Lactating patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| False neg ative rate of sentinel lymph node biopsy with indocyanine g reen in endometrial cancer | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Adverse events in indocyanine g reen 2. Incidence of lymphedema | — |
Contacts
Public ContactKeiichiro Nakamura
Okayama University Hospital
Outcome results
None listed